recently released new positive data from a phase I study
evaluating the pharmacokinetics of OMS824. OMS824 is Omeros' lead
compound in its phosphodiesterase 10 (PDE10) program.
The additional data further supports that OMS824 in comparison
to other PDE10 inhibitors in development can achieve superior
target engagement with lesser side effects. OMS824 was well
tolerated at the highest multiple-dose level administered.
Omeros plans to initiate phase II studies on OMS824 for
treating patients suffering from Huntington's disease and
schizophrenia by the end of 2013.
In May 2013, Omeros had reported that OMS824 achieved high
target occupancy without causing movement disorders seen with
other PDE10 inhibitors. The positron emission tomography (PET)
study evaluating OMS824 at lower doses revealed target engagement
of about 50%, more than other PDE10 inhibitors.
The new data shows about 200% increase in plasma concentration
over that of the dose used in the PET trial reported in May.
The phase I data supports the development of OMS824 for
patients suffering from Huntington's disease, schizophrenia and
other central nervous system disorders.
Meanwhile, we note that Omeros is currently looking to get a
candidate, OMS302, approved in the U.S. and EU for the treatment
of patients undergoing intraocular lens replacement (ILR)
surgery. Omeros expects to launch OMS302 both in the U.S. and the
EU in the second half of 2014, pending regulatory approval.
Omeros carries a Zacks Rank #3 (Hold). Stocks that currently
look attractive include
Biogen Idec Inc
. All three carry a Zacks Rank #1 (Strong Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
OMEROS CORP (OMER): Free Stock Analysis
To read this article on Zacks.com click here.